CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
Abstract We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not a...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2019-08-01
|
| Serija: | Journal of Hematology & Oncology |
| Teme: | |
| Online pristup: | http://link.springer.com/article/10.1186/s13045-019-0771-0 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|